Innoviva, Inc. reported $440M of revenue over the trailing twelve months, +19% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $440M (to Q2 2026). Net income: $357M, trailing twelve months to Q2 2026. Free cash flow: $189M, trailing twelve months to Q2 2026. Operating margin: 37%, trailing twelve months to Q2 2026.

INVAInnoviva, Inc.

Healthcare

$21.21+11% 1Y

$21.21

$16.6752 weeks$24.24

INVA as reported

Innoviva, Inc. reported $440M of revenue over the trailing twelve months, +19% on the year before. 11 reported series are charted on this page, each one as filed.

$440M

Revenue, trailing twelve months · to Q2 2026 · +19% against the twelve months before

Net income: $357M
Net income · +824% year on year · trailing twelve months to Q2 2026
Free cash flow: $189M
Free cash flow · −5.4% year on year · trailing twelve months to Q2 2026
Operating margin: 37%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for INVA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$440M	+19%	Q2 2026
Net income	$357M	+824%	Q2 2026
EPS	$4.11	+1042%	Q2 2026
Gross margin	72%	n/a	Q2 2026
Operating margin	37%	n/a	Q2 2026
Net margin	87%	n/a	Q2 2026
ROE	26%	n/a	Q2 2026
ROA	18%	n/a	Q2 2026
ROIC	15%	n/a	Q2 2026
Free cash flow	$189M	−5.4%	Q2 2026
P/E	5.16	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.